Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

11640,848

16/135913

September 19, 2018

Methods for selecting a cancer patient for immunotherapy comprise establishing a total passenger gene mutation burden from a tumor of a cancer patient, generating a background distribution for the mutational burden of the tumor, normalizing the total passenger gene mutation burden against the background distribution, and categorizing the cancer patient as an immunotherapy responder when the total passenger gene mutation burden is greater than the mean of the background distribution. When the cancer patient is an immunotherapy responder, the patient may be administered an immunotherapy regimen that comprises activation/inhibition of T cell receptors that promote T cell activation and/or prolong immune cytolytic activities.

REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY, US)

Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, US)

1. A method of treating a cancer patient with an antibody that binds to PD1, comprising administering the antibody that binds to PD1 to the cancer patient, whereby the cancer patient has been determined to have a tumor having a total passenger gene mutational burden that is greater than a background mutational burden of the tumor.

2. The method according to claim 1 , wherein the passenger gene mutational burden is determined to be greater than the background mutational burden by: establishing the total passenger gene mutational burden of the tumor; generating the background mutational burden; and normalizing the total passenger gene mutational burden against the background mutational burden.

3. The method according to claim 1 , wherein the background mutational burden is determined based on randomly selected genes of the tumor, and wherein a number of the randomly selected genes is equal to a number of passenger genes used to determine the total passenger gene mutational burden.

4. The method according to claim 2 , wherein normalizing the total passenger gene mutational burden against the background mutational burden comprises generating a z-score indicating a number of standard deviations from a mean of the background mutational burden.

5. The method according to claim 2 , further comprising categorizing a mutated gene of the tumor as a passenger gene.

6. The method according to claim 5 , wherein categorizing a mutated gene of the tumor as a passenger gene comprises selecting a mutated gene from the tumor and matching the mutated gene to a data structure comprising passenger genes established according to a passenger gene index.

7. The method according to claim 6 , wherein the passenger gene index comprises a correlation coefficient between a fraction of samples comprising the mutated gene obtained from a cancer patient cohort and a median number of mutated genes in each type of tumor within the cancer patient cohort.

8. The method according to claim 1 , wherein the antibody that binds to PD1 comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:21.

9. The method according to claim 2 , further comprising receiving genetic sequence data, wherein the genetic sequence data comprises a plurality of genes and is derived from the tumor of the patient.

10. The method according to claim 2 , wherein the total passenger gene mutational burden is greater than the background mutational burden when the normalized passenger gene mutational burden is at least about 1, at least about 1.5, at least about 2, at least about 2.5, at least about 3, or greater than 3 standard deviations greater than the mean of the background mutational burden.

11. The method according to claim 1 , wherein the total passenger gene mutational burden is determined based on one or more passenger genes having a genetic mutation rate that is highly correlated with overall tumor mutation frequencies.

12. The method according to claim 1 , wherein the cancer is cutaneous squamous cell cancer (CSCC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon/rectum adenocarcinoma (CORE), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), liver hepatocellular carcinoma (LIHC), brain lower grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), uterine corpus endometrioid carcinoma, or stomach adenocarcinoma.

13. The method according to claim 1 , wherein the cancer comprises a lung cancer.

14. The method according to claim 13 , wherein the lung cancer comprises non-small-cell lung carcinoma.

15. The method according to claim 1 , wherein the cancer comprises a skin cancer.

16. The method according to claim 15 , wherein the skin cancer comprises cutaneous squamous cell carcinoma (CSCC).

17. The method according to claim 1 , wherein the cancer comprises a cervical cancer.

18. The method according to claim 8 , wherein the cancer is cutaneous squamous cell cancer (CSCC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon/rectum adenocarcinoma (CORE), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), liver hepatocellular carcinoma (LIHC), brain lower grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), uterine corpus endometrioid carcinoma, or stomach adenocarcinoma.

19. The method according to claim 8 , wherein the cancer comprises a lung cancer.

20. The method according to claim 19 , wherein the lung cancer comprises non-small-cell lung carcinoma.

21. The method according to claim 8 , wherein the cancer comprises a skin cancer.

22. The method according to claim 21 , wherein the skin cancer comprises cutaneous squamous cell carcinoma (CSCC).

23. The method according to claim 8 , wherein the cancer comprises a cervical cancer.

24. The method according to claim 8 , wherein the antibody that binds to PD1 further comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 22.

25. The method according to claim 24 , wherein the cancer is cutaneous squamous cell cancer (CSCC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon/rectum adenocarcinoma (CORE), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), liver hepatocellular carcinoma (LIHC), brain lower grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), uterine corpus endometrioid carcinoma, or stomach adenocarcinoma.

26. The method according to claim 24 , wherein the cancer comprises a lung cancer.

27. The method according to claim 26 , wherein the lung cancer comprises non-small-cell lung carcinoma.

28. The method according to claim 24 , wherein the cancer comprises a skin cancer.

29. The method according to claim 28 , wherein the skin cancer comprises cutaneous squamous cell carcinoma (CSCC).

30. The method according to claim 24 , wherein the cancer comprises a cervical cancer.

31. The method according to claim 24 , wherein the antibody that binds to PD1 comprises cemiplimab.

32. The method according to claim 31 , wherein the cancer is cutaneous squamous cell cancer (CSCC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon/rectum adenocarcinoma (CORE), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), liver hepatocellular carcinoma (LIHC), brain lower grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), uterine corpus endometrioid carcinoma, or stomach adenocarcinoma.

33. The method according to claim 31 , wherein the cancer comprises a lung cancer.

34. The method according to claim 33 , wherein the lung cancer comprises non-small-cell lung carcinoma.

35. The method according to claim 31 , wherein the cancer comprises a skin cancer.

36. The method according to claim 35 , wherein the skin cancer comprises cutaneous squamous cell carcinoma (CSCC).

37. The method according to claim 31 , wherein the cancer comprises a cervical cancer.

4863849 September 1989 Melamede
4971903 November 1990 Hyman
5302509 April 1994 Cheeseman
5599675 February 1997 Brenner
5750341 May 1998 Macevicz
5763594 June 1998 Hiatt et al.
5798210 August 1998 Canard et al.
5939292 August 1999 Gelfand et al.
6001566 December 1999 Canard et al.
6090549 July 2000 Mirzabekov et al.
6210891 April 2001 Nyren et al.
6258568 July 2001 Nyren
6401267 June 2002 Drmanac
6620584 September 2003 Chee et al.
6664079 December 2003 Ju et al.
6984720 January 2006 Korman et al.
7034121 April 2006 Carreno et al.
7057026 June 2006 Barnes et al.
7605238 October 2009 Korman et al.
20050037398 February 2005 Gelfand et al.
20050130173 June 2005 Leamon et al.
20060134633 June 2006 Chen et al.
20090088327 April 2009 Rigatti et al.
20090325172 December 2009 Milton et al.
20100028885 February 2010 Balasubramanian et al.
20150203579 July 2015 Papadopoulos et al.
20150203580 July 2015 Papadopoulos et al.
20170101472 April 2017 Ullman et al.
2017-507650 March 2017
WO-01/23411 April 2001
WO-05/024010 March 2005
WO-2017/062888 April 2017
WO-2017/112775 June 2017
WO-2017/151517 September 2017
WO 2017/151524 September 2017
WO-2017/151524 September 2017
WO-2018/068028 April 2018

Spencer et al (Am Soc Clin Educ Book, May 2016, 35: e493-e503). cited by examiner
Beasley et al (Clinical Skin Cancer, 2016, 1(2): 75-81). cited by examiner
Topalian et al: “Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy”, Nature Reviews. Cancer, vol. 16, No. 5, Apr. 15, 2016 (Apr. 15, 2016), pp. 275-287. cited by applicant
Campesato et al: ““Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice””, Oncotarget, (2015) Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741447/pdf/oncotarget-06-34221.pdf. cited by applicant
Li et al: ““Mining the coding and non-coding genome for cancer drivers””, Cancer Letters, New York, NY, US, vol. 369, No. 2, (2015), pp. 307-315. cited by applicant
McFarland et al, “The Damaging Effect of Passenger Mutations on Cancer Progression”, Cancer Res. (2017),77(18):4763-4772. cited by applicant
Charoentong et al: “Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade”, Cell Reports, vol. 18, No. 1, Jan. 1, 2017 (Jan. 1, 2017), pp. 248-262. cited by applicant
International Search Report and Written Opinion were dated Dec. 19, 2018 by the International Searching Authority for International Application No. PCT/US2018/051755, filed on Sep. 19, 2019 (Applicant—Regeneron Pharmaceuticals, Inc.) (15 Pages). cited by applicant
Notification of Reasons for Rejection were dated Jul. 20, 2021 by the JP Patent Office for JP Application No. 2020-516633, filed on Sep. 19, 2019 (Applicant—Regeneron Pharmaceuticals, Inc.) (4 Pages of Translation). cited by applicant
Nakatsura, T. Era of cancer immunotherapy has come. Japanese J of Clinical Immunology, 39(3) (2016), 164-171 (abstract). cited by applicant
Topalian et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer 16 (2016), 275-287. cited by applicant
Topalian et al. Immunotherapy: The path to win the war on cancer? Cell 16(2) (2015), 185-186. cited by applicant
Written Opinion and Search Report were dated Nov. 29, 2021 by the SG Patent Office for SG Application No. 11202002282, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (6 Pages of Written Opinion; 3 pages of Search Report). cited by applicant
Decision of Refusal was dated Nov. 15, 2021 by the RU Patent Office for RU Application No. 2020113600, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (7 Pages of Translation). cited by applicant
Examination Report was dated Nov. 10, 2021 by the AU Patent Office for AU Application No. 2018336785, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (3 Pages). cited by applicant
Examination Report was dated Jul. 7, 2021 by the AU Patent Office for AU Application No. 2018336785, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (5 Pages). cited by applicant
Office Action was dated Apr. 7, 2021 by the CA Patent Office for CA Application No. 3,075,927, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (5 Pages). cited by applicant
Office Action was dated Jan. 3, 2022 by the KR Patent Office for CA Application No. 3,075,927, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (4 Pages of translation). cited by applicant
Altschul et al. “Issues in searching molecular sequence databases” Nature Genet. 6(2):119-29 (1994). cited by applicant
Corpet et al. “Multiple sequence alignment with hierarchical clustering” Nucl. Acids Res. 16:10881-90 (1988). cited by applicant
Dressman et al., “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations” Proc. Natl. Acad. Sci. USA 100:8817-8822 (2003). cited by applicant
Higgins et al. “Fast and sensitive multiple sequence alignments on a microcomputer” CABIOS 5:151-153 (1989). cited by applicant
Huang et al. “Parallelization of a local Similarity Search Algorithm” Comput Appl Biosci. 8(2):155-65. (1992). cited by applicant
Mitra et al., “Digital genotyping and haplotyping with polymerase colonies” Proc. Natl. Acad. Sci. USA 100(10):5926-5931 (2003). cited by applicant
Pearson et al. “Improved tools for biological sequence comparison” Proc. Natl. Acad. Sci. USA 85(8):2444-8 (1988). cited by applicant
Ronaghi et al., “A sequencing method based on real-time pyrophosphate” Science 281:363 (1998). cited by applicant
Shendure et al. “Accurate multiplex polony sequencing of an evolved bacterial genome” Science 309(5741):1728-1732 (2005). cited by applicant
Smith et al. “Comparison of biosequences” Advances in Applied Mathematics, 2(4): 482-489 (1981). cited by applicant
Stratton MR et al. “The cancer genome”(2009) Nature. 458 (7239): 719-24. cited by applicant
Postow MA, et al. “Immune Checkpoint Blockade in Cancer Therapy”, J of Clinical Oncology, 33/17, pp. 1974-1982, Jun. 10, 2015. cited by applicant
Sharma et al. “The future of immune checkpoint therapy”, Science 348/6230, pp. 56-61, Apr. 3, 2015. cited by applicant
Migden MR, “PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma”, The New England Journal of Medicine, pp. 341-351, Jul. 26, 2018. cited by applicant
Office Action was dated Mar. 21, 2022 by the CA Patent Office for CA Application No. 3,075,927, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (6 Pages). cited by applicant
U.S. Appl. No. 62/560,955, filed Sep. 20, 2017, Wei Keat Lim. cited by applicant
PCT, PCT/US2018/051755, Sep. 19, 2018, Regeneron Pharmaceuticals Inc. cited by applicant
Office Action was dated Jun. 24, 2021 by the KR Patent Office for KR Application No. 10-2020-7018681, filed on Jun. 29, 2020 (Applicant—Regeneron Pharmaceuticals, Inc.) (7 Pages). cited by applicant
Office Action was dated Feb. 23, 2022 by the KR Patent Office for KR Application No. 10-2020-7018681, filed on Jun. 29, 2020 (Applicant—Regeneron Pharmaceuticals, Inc.) (4 Pages). cited by applicant
Office Action was dated Jun. 17, 2022 by the UA Patent Office for UA Application No. 202002442, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (3 Pages). cited by applicant

edspgr.11640848